Latest News

{{header-clinical-trials-navigation}} A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in Metastatic Castration Sensitive Prostate Cancer With and Without DNA Repair Mutations Condition: Prostate Cancer Intervention: Drug: Cabazitaxel Drug: Carboplatin Drug: Abiraterone Drug: Prednisone Purpose: This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study […]

{{header-clinical-trials-navigation}} A Phase I/II Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer Condition: Prostate Cancer Metastatic Intervention: Drug: LAE001 Drug: Placebo Purpose: This study is a multicenter phase I/II study of the treatment of patients with metastatic prostate cancer. The objective of Phase I part is to study […]

{{header-clinical-trials-navigation}} Phase II, Open-label, Single-center Study Evaluating Safety and Activity of Androgen Deprivation Therapy Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer (mHSPC) Condition: Prostate Cancer Metastatic Intervention: Drug: REGN2810 Drug: Degarelix Drug: Leuprolide Acetate Drug: Docetaxel Purpose: The primary objective is to determine the safety and activity of combined hormonal chemoimmunotherapy in a […]

{{header-clinical-trials-navigation}} China ARCHES: A Multicenter, Phase 3, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Condition: Metastatic Hormone Sensitive Prostate Cancer Intervention: Drug: Enzalutamide Drug: Placebo Drug: Androgen deprivation therapy (ADT) Purpose: The purpose […]

{{header-clinical-trials-navigation}} A Study Comparing Intermittent Androgen Depriving Therapy With Or Without Salvage High-Dose Intensity Modulation Radiotherapy (IG-IMRT)To Oligometastatic Pelvic Lymph Nodes In Biochemically-relapsing Prostate Cancer Patients. Condition: Prostate Cancer, Oligometastasis Intervention: Drug: IADT Combination Product: IADT + radiotherapy Purpose: Metastatic prostate cancer has traditionally been regarded as an incurable dissemination of disease, and treatment is […]

{{header-clinical-trials-navigation}} A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) Condition: Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Small Cell Carcinoma, Bladder Squamous Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Infiltrating Bladder Lymphoepithelioma-Like Carcinoma, Infiltrating Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating […]

{{header-clinical-trials-navigation}} A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney. Condition: Kidney Cancer, Prostate Cancer, Bladder Cancer Purpose: Identifying clinical factors such as medication, background diseases and blood tests that effect the course of disease in cancer patients can help physicians to […]

{{header-clinical-trials-navigation}} Prospective Randomized Phase II Trial: Comparing the Prognostic Value of Routine Lymphadenectomy Versus Lymphadenectomy Only for Lymph Nodes Enlargement Found in Preoperative Imaging or During Surgery Undergoing Nephroureterectomy in Patients With Primary Upper Tract Urothelial Carcinoma Condition: Lymph Node Dissection Intervention: Procedure: Routine Template-based lymphadenectomy Procedure: LND only for lymph nodes enlargement found in […]

{{header-clinical-trials-navigation}} Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer Condition: Renal Cell Carcinoma Intervention: Biological: High Dose IL-2 Radiation: SBRT Purpose: All patients will receive IL-2 (14 planned doses with an additional cycle 14 days after the first). Responding […]

People of all sexes can have risk genes that are often assumed to affect only women. A new name could aid cancer prevention and treatment, argues Colin C. Pritchard. I recently had a conversation with my parents about genetic testing for cancer risk. “You mean men also have the BRCA genes?” asked my dad. “I […]